XML 64 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
Disclosure about Fair Value of Financial Instruments (Tables)
12 Months Ended
Dec. 31, 2018
Fair Value Disclosures [Abstract]  
Carrying amounts and estimated fair values of financial instruments The carrying amounts and estimated fair values of our financial instruments are as follows as of the dates presented (in thousands):
 
 
December 31, 2018
 
December 31, 2017
 
 
Carrying
 
Fair
 
Carrying
 
Fair
 
 
Amount
 
Value
 
Amount
 
Value
Financial assets:
 
 
 
 
 
 
 
 
Mortgage loans receivable
 
$
249,071

 
$
257,337

 
$
306,120

 
$
332,508

Other real estate loans receivable
 
81,268

 
82,742

 
121,379

 
125,480

Equity securities
 
11,286

 
11,286

 
7,269

 
7,269

Cash and cash equivalents
 
215,376

 
215,376

 
243,777

 
243,777

Restricted cash
 
100,753

 
100,753

 
65,526

 
65,526

Foreign currency forward contracts and cross currency swaps
 
94,729

 
94,729

 
15,604

 
15,604

 
 
 
 
 
 
 
 
 
Financial liabilities:
 
 
 
 
 
 
 
 
Borrowings under unsecured credit facilities
 
$
1,147,000

 
$
1,147,000

 
$
719,000

 
$
719,000

Senior unsecured notes
 
9,603,299

 
10,043,797

 
8,331,722

 
9,168,432

Secured debt
 
2,476,177

 
2,499,130

 
2,608,976

 
2,641,997

Foreign currency forward contracts and cross currency swaps
 
71,109

 
71,109

 
38,654

 
38,654

 
 
 
 
 
 
 
 
 
Redeemable OP unitholder interests
 
$
103,071

 
$
103,071

 
$
97,476

 
$
97,476

The Market approach utilized to measure fair value of financial assets and liabilities on recurring basis The following summarizes items measured at fair value on a recurring basis (in thousands):
 
 
Fair Value Measurements as of December 31, 2018
 
 
Total
 
Level 1
 
Level 2
 
Level 3
Equity securities
 
$
11,286

 
$
11,286

 
$

 
$

Foreign currency forward contracts and cross currency swaps, net asset (liability)(1)
 
23,620

 

 
23,620

 

Redeemable OP unitholder interests
 
103,071

 

 
103,071

 

Totals 
 
$
137,977

 
$
11,286

 
$
126,691

 
$


(1) Please see Note 11 for additional information.